Spyre Therapeutics Inc [SYRE] stock is trading at $37.48, up 4.34%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SYRE shares have gain 9.72% over the last week, with a monthly amount glided 34.43%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Spyre Therapeutics Inc [NASDAQ: SYRE] stock has seen the most recent analyst activity on September 04, 2024, when Wedbush initiated its Outperform rating and assigned the stock a price target of $45. On May 02, 2024, Robert W. Baird initiated with a Outperform rating and assigned a price target of $50 on the stock. Wells Fargo upgraded its rating to a Overweight and increased its price target to $35 on March 01, 2024. BTIG Research initiated its recommendation with a Buy and recommended $32 as its price target on December 20, 2023. Jefferies started tracking with a Buy rating for this stock on December 11, 2023, and assigned it a price target of $31. In a note dated December 11, 2023, Guggenheim initiated an Buy rating and provided a target price of $44 on this stock.
Spyre Therapeutics Inc [SYRE] stock has fluctuated between $8.43 and $47.97 over the past year. Currently, Wall Street analysts expect the stock to reach $43.33 within the next 12 months. Spyre Therapeutics Inc [NASDAQ: SYRE] shares were valued at $37.48 at the most recent close of the market. An investor can expect a potential return of 15.61% based on the average SYRE price forecast.
Analyzing the SYRE fundamentals
Spyre Therapeutics Inc [NASDAQ:SYRE] reported sales of 0.00M for the trailing twelve months, which represents a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 0.07% with Operating Profit Margin at -149.88%, Pretax Profit Margin comes in at -178.45%, and Net Profit Margin reading is -178.48%. To continue investigating profitability, this company’s Return on Assets is posted at -0.43, Equity is -1.6 and Total Capital is -0.38.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 36.24 points at the first support level, and at 35.01 for the second support level. However, for the 1st resistance point, the stock is sitting at 38.38, and for the 2nd resistance point, it is at 39.29.
Ratios To Look Out For
For context, Spyre Therapeutics Inc’s Current Ratio is 19.70. As well, the Quick Ratio is 19.70, while the Cash Ratio is 2.04.
Transactions by insiders
Recent insider trading involved Albers Jeffrey W., Director, that happened on Oct 25 ’24 when 300.0 shares were sold. Director, SESSIONS, LLC completed a deal on Oct 25 ’24 to buy 7000.0 shares. Meanwhile, Chief Financial Officer Burrows Scott L sold 18531.0 shares on Sep 03 ’24.
